News



  • Valneva to Conduct Investor and Partnering Meetings During the Annual J.P. Morgan Healthcare Conference2017-12-04

    Valneva to Conduct Investor and Partnering Meetings During the Annual J.P. Morgan Healthcare Conference

    Lyon (France), December 4, 2017 – Valneva SE today announces that its senior
    management team will hold investor and partnering meetings in San Francisco
    during the 36th Annual J.P. Morgan Healthcare Conference

    PDF Download
    auf Deutsch lesen
  • Valneva Expands its Commercial Operations and Establishes US Infrastructure2017-11-30

    Valneva Expands its Commercial Operations and Establishes US Infrastructure

    Lyon (France), November 30, 2017 – Valneva SE, a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, today announces further expansion of its global commercial infrastructure with Valneva USA. The fully-owned commercial subsidiary will take direct control of sales and marketing of IXIARO® in the U.S. private market with the aim of accelerating sales growth of the vaccine.

    PDF Download
    auf Deutsch lesen
  • Valneva Reports Strong Operational Performance for the First Nine Months of 20172017-11-09

    Valneva Reports Strong Operational Performance for the First Nine Months of 2017

    Lyon (France), November 9, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing and commercialising innovative, life-saving vaccines, reported today its consolidated financial results for the first nine months of the year ended September 30, 2017.
    • Total revenues of €79.8 million in the first nine months 2017 compared to €70.7 million in the first nine months of 2016 benefiting from a 20% year-on-year growth in product sales. Full year revenue expectation confirmed in the previously guided range of €105-115 million.
    • EBITDA at €12.3 million in the first nine months of 2017 compared to €3.5 million in the first nine of months 2016. As announced in first half results, following major R&D progress, Valneva expects higher R&D costs in 2017 than initially anticipated of €23-25 million. Despite this, the Company increases its full year EBITDA guidance to €10m - €13 million compared to previous guidance of €5 - €10 million.
    • Positive operating cash flow of €18.2 million in the first nine months of 2017 brought cash position to €43.8 million at the end of September 2017.
    • As planned, noting the increase in R&D expenditure driven by progression of key R&D programs, under the €25 million loan agreement announced in July 2016 with the European Investment Bank, Valneva expects to draw down a further €5 million prior to the end of this year.

    Press release
    Financial report
    Analyst presentation
    Webcast



    auf Deutsch lesen
  • Valneva Signs $39.6 Million IXIARO® Supply Contract with US Government2017-11-07

    Valneva Signs $39.6 Million IXIARO® Supply Contract with US Government

    Lyon (France), November 7, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative, life-saving vaccines, announces today the signing of a $39.6 million one year contract with the US Government’s Department of Defense for the supply of its Japanese encephalitis (JE) vaccine IXIARO®. The new agreement will supplement the initial contract Valneva signed with the US military in March 2016 as the maximum quantity of doses allowed in the precedent contract was reached earlier than expected.

    PDF Download
    auf Deutsch lesen
  • Valneva to Present at Jefferies and Stifel 2017 Healthcare Conferences2017-11-06

    Valneva to Present at Jefferies and Stifel 2017 Healthcare Conferences

    Lyon (France), November 06, 2017 – Valneva SE (“Valneva” or “the Company”), a leading commercial stage biotech company focused on developing innovative lifesaving vaccines, today announces that Thomas Lingelbach, President & Chief Executive Officer will provide a corporate presentation at the Stifel Healthcare Conference in New York on Tuesday, November 14, 2017 and at the Jefferies Healthcare Conference in London on Thursday, November 16, 2017.

    PDF Download
  • Valneva Reports Robust H1 2017 Financial Results & Major R&D Progress Company to Continue Delivering Strong Commercial Performance while Focusing on Advancing Leading R&D Programs2017-08-31

    Valneva Reports Robust H1 2017 Financial Results & Major R&D Progress
    Company to Continue Delivering Strong Commercial Performance while Focusing on Advancing Leading R&D Programs


    Lyon (France), August 31, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative, life-saving vaccines, reported today its consolidated financial results for the first half ended June 30, 2017.

    • Total revenues and grants of €55.4 million in H1 2017 (with total product sales growth of 17.5% compared to H1 2016)
    • EBITDA increased strongly in H1 2017 reaching €7.6 million (vs. €4.7 million in H1 2016)
    • Net loss was significantly reduced in H1 2017 to €4.4 million compared to a net loss of €39.5 million in H1 2016
    • Positive operating cash flow amounted to €16.6 million in H1 2017 (vs. €3.9 million in H1 2016) bringing Valneva’s cash position to €47.3 million at the end of June 2017

    A webcast for financial analysts, fund managers, investors and journalists will be held today at 2:00 pm (CET). A replay will be available on the Company’s website. Please refer to this link: Webcast

    Press release
    Financial report
    Analyst presentation
    Webcast Link
    auf Deutsch lesen
  • Valneva Announces Expansion of its Management Board – Strengthening Senior Management for Future Growth2017-08-01

    Valneva Announces Expansion of its Management Board – Strengthening Senior Management for Future Growth

    • Appointment of David Lawrence as Chief Financial Officer (CFO)
    • Appointment of Wolfgang Bender, MD, PhD as Chief Medical Officer (CMO)

    Lyon (France), August 1, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, is pleased to announce the expansion of its Management Board with two new appointments: David Lawrence as Chief Financial Officer (CFO) and Wolfgang Bender, MD, PhD as Chief Medical Officer (CMO). Mr. Lawrence's and Dr. Bender's appointments by the Company´s Supervisory Board will become effective on August 7th and September 1st respectively.

    PDF Download
    auf Deutsch lesen
  • Valneva and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus2017-07-26

    Valneva and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus

    Lyon (France), July 26, 2017 - Valneva SE (VLA), a fully integrated, commercial stage biotech company focused on developing innovative, life-saving vaccines, announces today that it has granted Emergent BioSolutions Inc. (NYSE:EBS) exclusive worldwide rights to its Zika vaccine technology ZIKV.

    PDF Download
    auf Deutsch lesen
  • Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA152017-07-22

    Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15

    Lyon (France), July 24, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its Lyme disease vaccine candidate VLA15.

    PDF Download
    auf Deutsch lesen
  • Valneva Announces Successful Outcome of its AGM and the Appointment of two new Supervisory Board Members; The Company Confirms its Growth Strategy and R&D Outlook2017-06-30

    Valneva Announces Successful Outcome of its AGM and the Appointment of two new Supervisory Board Members;
    The Company Confirms its Growth Strategy and R&D Outlook

    Lyon (France), June 30, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announces that all the resolutions proposed by the Management Board were adopted by the shareholders at its Combined General Meeting (AGM) held in Lyon on June 29, 2017.

    PDF Download
    auf Deutsch lesen
  • Valneva Announces the Availability of Documentation for its Meetings of Shareholders2017-06-08

    Valneva Announces the Availability of Documentation for its Meetings of Shareholders

    Lyon (France), June 8, 2017 – The Shareholders of Valneva SE (“Valneva” or “the Company”), are invited to participate in the Company’s Combined General Meeting to be held on June 29, 2017 at 2:30 p.m. CET, at the Novotel Lyon Confluence, 3 rue Paul Montrochet, 69002 Lyon, France. The Combined General Meeting will follow a Special Meeting of Convertible Preferred Share holders to be held at the same location at 2:00 p.m. that same day.

    The preliminary notice of meetings containing the agenda, the proposed resolutions and instructions for participation and voting was published in the Bulletin des Annonces Légales Obligatoires (BALO) on May 22, 2017. Documents and information relating to the meetings are available here.

    PDF Download
  • Valneva to Present at Jefferies 2017 Global Healthcare Conference in New York2017-06-06

    Valneva to Present at Jefferies 2017 Global Healthcare Conference in New York

    Lyon (France), June 06, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that Thomas Lingelbach, President & Chief Executive Officer will provide a corporate presentation at the Jefferies 2017 Global Healthcare Conference in New York on Thursday, June 8, 2017 at 10:30 AM EDT.

    PDF Download
    auf Deutsch lesen
  • Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA; Reaffirms Financial Guidance and Pipeline Outlook for 20172017-05-11

    Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017

    Robust Q1 financial results – confirming financial self-sustainability strategy
    + Total revenues and grants of €29.1 million in Q1 2017 (vs €24.7 million in Q1 2016) driven by a strong increase in vaccine sales;
    + Q1 product sales performance up 26.7% compared to Q1 2016, mainly driven by IXIARO® sales to the US military and strong sales in the travel market;
    + EBITDA of €3.4 million and operating profit of €0.5 million in Q1 2017 compared to an operating loss of €2.7 million in Q1 2016;
    + Net loss reduced to €1.7 million in Q1 2017 compared to a net loss of €5.0 million in Q1 2016;
    + Cash position at €45.2 million at end of March 2017.

    Press release
    Financial report
    Analyst presentation
    Webcast link
    auf Deutsch lesen
  • Valneva Announces Signing of a New EB66® Commercial License with Bavarian Nordic2017-04-18

    Valneva Announces Signing of a New EB66® Commercial License with Bavarian Nordic

    • Valneva’s EB66® cell-line licensed to Bavarian Nordic for MVA-BN® based product candidates
    • Valneva to support process development

    Lyon (France), April 18, 2017 - Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that it has entered into a commercial agreement with Danish biotech company Bavarian Nordic (OMX: BAVA, OTC:BVNRY), for the production of poxvirus-based vaccines using Valneva´s EB66® cell-line technology.

    PDF Download
    auf Deutsch lesen
  • Valneva to Present at the 17th World Vaccine Congress in Washington D.C.2017-04-10

    Valneva to Present at the 17th World Vaccine Congress in Washington D.C.

    Lyon (France), April 10, 2017 – Valneva SE (“Valneva” or “the Company”), a leading pure play vaccine company, announced today that it will be holding two presentations on Lyme disease and mosquito-transmitted diseases on April 11, 2017 at the 17th World Vaccine Congress in Washington DC.

    PDF Download
    auf Deutsch lesen
  • Valneva Reports Best Financial Results in the Company’s History with its First Year of Positive EBITDA in 20162017-03-23

    Valneva Reports Best FY Results in the Company’s History with its First Year of Positive EBITDA in 2016

    The Company expects to continue showing a strong financial performance in 2017

    • Total revenues and grants of €97.9 million in 2016 (vs €83.3 million in 2015) driven mainly by a 73.1% increase in IXIARO®/JESPECT® revenues;
    • Valneva reported a positive EBITDA of €2.8 million in 2016 (vs. an EBITDA loss of €8.5 million in 2015);
    Lyon (France), March 23, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, reported today its fourth quarter and full year financial results ending December 31, 2016. The annual financial report including the consolidated financial statements 2016 are available on the Company’s website www.valneva.com.

    A webcast for financial analysts, fund managers, investors and journalists will be held today at 2:00 pm (CET). A replay will be available on the Company’s website. Please refer to this link.

    PDF Download
    auf Deutsch lesen
  • Valneva Announces Publication of its Registration Document2017-03-23

    Valneva Announces Publication of its Registration Document

    Lyon (France), March 23, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, announces today the publication of its 2016 Registration Document (“Document de Référence”), filed with the French Financial Market Authority (“Autorité des Marchés Financiers”) under the filing number D.17-0205 on March 22, 2017.

    PDF Download
  • Valneva Reports Strong Q4 and FY 2016 Business Performance; Expects Further Growth in Sales and EBITDA, R&D Progress in 20172017-02-23

    Valneva Reports Strong Q4 and FY 2016 Business Performance;
    Expects Further Growth in Sales and EBITDA, R&D Progress in 2017

    The Company today announced its unaudited FY 2016 revenues and cash-balance, estimated EBITDA and 2017 outlook

    Lyon (France), February 23, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, published today its unaudited revenues and cash balance, and estimated EBITDA for the fourth quarter and the full year ended December 31, 2016. Audited full year financial results are scheduled to be released on March 23, 2017.

    PDF Download
    auf Deutsch lesen
  • Valneva Supports World Encephalitis Day on February 22, 20172017-02-17

    Valneva Supports World Encephalitis Day on February 22, 2017 

    WED_logo.jpg

    As the manufacturer and supplier of IXIARO® – the only licensed and recommended Japanese encephalitis (JE) vaccine in the US and Europe, Valneva SE is proud to support The Encephalitis Society to raise the awareness of the impact of encephalitis on World Encephalitis Day (WED). Encephalitis, a swelling of the brain, is a devastating condition which affects 500,000 people globally each year.

    PDF Download
  • Valneva Announces a New Research License Agreement with MSD Animal Health for the Development of Vaccines in the EB66® Cell Line2017-01-05

    Valneva Announces a New Research License Agreement with MSD Animal Health for the Development of Vaccines in the EB66® Cell Line

    Lyon (France), January 5, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines, today announced that it has signed a research license agreement with MSD Animal Health, known as Merck Animal Health in the United States and Canada.

    PDF Download
    auf Deutsch lesen
Please update your browser...